Avalo Therapeutics Inc. (AVTX)
AVTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1534120/000153412026000011/0001534120-26-000011-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | AVTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2015 |
| SEC CIK | 0001534120 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $59K |
| Net income | -$78.3M |
| Operating income | -$72.9M |
| Net margin | -132642.4% |
| Operating margin | -123601.7% |
| Revenue growth | -86.6% |
| Cash | $15.9M |
| Total assets | $116.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 7223.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $65.0M cash; operating cash flow -$15.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 57,823,083 (2026-11-02); 18,133,968 a year earlier; 192,382,419 three years earlier. 3y figure adjusted for splits (1-for-240 overall). | Cover page 2026-11-02 |
| Reverse splits, 3 years | 1; latest 1-for-240 on 2023-12-29 | Source 2023-12-29 |
| Shelf and offerings, 12 months | 3 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-11-05 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Jericho, New York, United States | PCAOB Form AP 2026-04-07 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $8.5M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$18.9M | -$11.5M | $65.0M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | Not filed | -$36.4M | -$20.0M | $85.4M | No debt tags | Needs four quarters | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | Not filed | -$19.6M | -$17.7M | $25.0M | No debt tags | Needs four quarters | 10-Q 2026-05-13 |
| Q4 2025 2025-12-31 | $59K | -$13.7M | -$14.2M | $15.9M | No debt tags | $59K | 10-K 2026-03-23 |
| Q3 2025 2025-09-30 | $0 | -$30.6M | -$16.4M | $27.0M | No debt tags | Needs four quarters | 10-Q 2025-11-06 |
| Q2 2025 2025-06-30 | Not filed | -$20.8M | -$11.4M | $42.3M | No debt tags | Needs four quarters | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | Not filed | -$13.1M | -$9.5M | $125.0M | No debt tags | Needs four quarters | 10-Q 2026-05-13 |
| Q4 2024 2024-12-31 | $192K | -$35.3M | -$15.0M | $134.5M | No debt tags | $441K | 10-K 2026-03-23 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-11-05 |
| Latest annual report | 10-K | 2026-03-23 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report FORM 8-K | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-10 |
Source: SEC EDGAR submissions feed, 1,006 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +12.0% |
| 1 month | -35.4% |
| 3 months | -60.1% |
| Year to date | -57.3% |
| 1 year | -47.3% |
| From 52-week high | -66.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CTMX | CytomX Therapeutics Inc. | $1.99 | -2.70% | $432.7M |
| BLSM | BlossomHill Therapeutics Inc. | $13.65 | -2.64% | $433.9M |
| ASMB | Assembly Biosciences Inc. | $21.29 | +0.80% | $436.0M |
| EOLS | Evolus Inc. | $6.63 | -4.74% | $438.8M |
| ARVN | Arvinas Inc. | $6.77 | -0.73% | $443.3M |
| PRTA | Prothena Corporation plc | $7.97 | -2.33% | $409.3M |
| MPLT | MapLight Therapeutics Inc. | $6.90 | -4.83% | $446.9M |
| DMAC | DiaMedica Therapeutics Inc. | $8.33 | -5.23% | $449.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier